| EPD0585 | Dynamic partnership to redefine community engagement in HIV programming in Nigeria | E-poster | Social and behavioural aspects and approaches to HIV |
| EPA0038 | Duration of antiretroviral therapy is a determinant of the frequency of NKG2C+CD57+ adaptive NK cells in persons living with cytomegalovirus and HIV infections | E-poster | Host immune responses, vaccines and immunotherapies |
| EPA0085 | Dual therapy of Interleukin-21 and anti-α4β7 antibody administration during ART-treated SIV promotes immunological responses and ameliorates dysbiosis in rhesus macaques | E-poster | Novel treatment and prevention strategies |
| OAC0404 | Drug-drug interaction between emtricitabine/tenofovir alafenamide (FTC/TAF)-based PrEP and feminizing hormones in transgender women: peripheral blood mononuclear cells and urine analysis from the iFACT3 study | Oral abstract session with live Q&A | HIV prevention research |
| EPB0153 | Drug Resistant Tuberculosis (DR-TB) detection among new, previously treated TB cases, and people living with HIV in Western and Southern highlands, Tanzania | E-poster | Co-infections (including opportunistic infections) |
| OAE0103 | Drivers of pre-exposure prophylaxis choice for transgender women in 11 countries in Asia: a discrete choice experiment | Oral abstract session with live Q&A | Implementation science and scale up of prevention |
| TUPEA11 | DPP9 inhibitors: a novel class of drugs for clearance of HIV-1 infected cells | Poster exhibition | Novel treatment and prevention strategies |
| EPD0576 | DoxyPEP use, acceptability, and associated health behaviors among a multisite sample of men who have sex with men and transgender women | E-poster | Social and behavioural aspects and approaches to HIV |
| EPD0726 | Doubts about HIV self-test accuracy and fear of psychological trauma deter men’s adoption of HIV self-test kits – A qualitative study in Eswatini | E-poster | Sexuality, gender, relationships and sexual cultures |
| OALBX0102 | Doravirine/Islatravir (100mg/0.75mg) once daily compared to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as Initial HIV-1 treatment: 48 week results from a double-blind phase 3 trial | Oral abstract session with live Q&A | Antiretroviral therapies and clinical issues in adults |